Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Making Gains Against Triple-Negative Breast Cancer

Executive Summary

Researchers reported on new approaches to the knotty problem of triple-negative breast cancer, using genomics to identify ways of targeting the intractable disease with drugs already in the industry pipeline, at the San Antonio Breast Cancer Symposium Dec. 4-8.

You may also be interested in...



Generex Likes Chances For Partnering AE37 Breast Cancer Vaccine

The vaccine trains specialized immune cells to act against a HER2 peptide. Created using Antigen Express’ Ii-Key Hybrid platform, Generex says AE37 has none of the restrictions that will limit the market potential of other HER2 peptide vaccines in development.

HDAC Inhibitor Mysteries Remain As Candidates Advance

With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.

Sanofi-Aventis Could Refocus Development For PARP Inhibitor Iniparib

The French pharma is standing by the first-in-class drug, which failed in a Phase III trial in triple-negative breast cancer, saying it conferred a benefit in heavily pretreated patients.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054996

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel